The treatment landscape for non-small cell lung cancer (NSCLC) has been transformed by biomarker-driven therapy, but the administrative infrastructure required to support comprehensive molecular profiling, targeted therapy prior authorization, and multidisciplinary tumor board operations has not kept pace. Thoracic oncology programs now routinely order 15 or more biomarker tests for newly diagnosed NSCLC patients — including next-generation sequencing (NGS) panels, individual FISH assays, and PD-L1 immunohistochemistry — and each test must be tracked, reconciled, and reviewed before first-line treatment can begin. Virtual assistants (VAs) trained in thoracic oncology operations are managing the administrative coordination layer of these complex workflows, enabling lung cancer programs to deliver faster, guideline-concordant care.
EGFR, ALK, ROS1, PD-L1, and Comprehensive Molecular Result Tracking
NCCN and IASLC guidelines for advanced NSCLC require biomarker testing for EGFR exon 19 deletions and exon 21 L858R mutations, ALK rearrangements, ROS1 fusions, KRAS G12C mutation, MET exon 14 skipping, BRAF V600E, RET fusions, NTRK fusions, and PD-L1 expression level. For a practice diagnosing 10 to 20 new NSCLC cases per month, managing 10 or more pending molecular results per patient — with varying lab turnaround times from tissue NGS (7 to 14 days), FISH assays (5 to 10 days), and IHC PD-L1 (3 to 5 days) — is a coordination challenge that exceeds manual capacity.
VAs maintain a molecular result tracking log for all newly diagnosed NSCLC patients, with daily checks of pathology and reference lab portals. When results arrive, VAs update the tracking log, flag any actionable mutations for urgent clinical review, and confirm that all expected biomarkers have returned before the patient's treatment planning appointment. The International Association for the Study of Lung Cancer (IASLC) 2023 Biomarker Testing Survey found that result tracking failures contributed to 19% of delays in first-line therapy initiation at community thoracic programs.
NCCN Tumor Board Case Preparation
Multidisciplinary tumor boards are a standard of care for lung cancer and a CoC accreditation requirement for cancer programs. Weekly thoracic tumor board requires case preparation: assembling imaging reports (CT chest/abdomen/pelvis, PET/CT, brain MRI), pathology reports, molecular testing results, and clinical history into a structured case summary for presentation. For programs presenting 10 to 20 cases per conference, the preparation burden is substantial and typically falls on oncology nurses or coordinators who are simultaneously managing patient care responsibilities.
VAs prepare tumor board case packets by pulling relevant reports from the EHR, organizing them into structured presentation formats, and uploading them to the tumor board platform (Epic Tumor Board, Veeva Vault, or shared drive). VAs also track which patients have been presented, document tumor board recommendations in the medical record, and follow up on action items generated at conference.
Immunotherapy Prior Authorization
For NSCLC patients without a targetable mutation, first-line immunotherapy — either pembrolizumab monotherapy (if PD-L1 ≥50%) or platinum-doublet plus immunotherapy combination — is standard. Commercial payer prior authorization for pembrolizumab, nivolumab, atezolizumab, and durvalumab requires PD-L1 documentation, staging documentation, and NCCN pathway citation. Approvals are frequently time-limited and require re-authorization at 6 to 12 month intervals.
VAs manage the full immunotherapy PA workflow: compiling biomarker documentation, preparing prior authorization requests, submitting through payer portals, tracking approval timelines, and initiating re-authorization before expiration. For maintenance therapy with durvalumab following chemoradiation for stage III NSCLC, VAs also coordinate the treatment completion documentation required to justify maintenance authorization.
Liquid Biopsy Coordination for Resistance Mutation Detection
At disease progression, liquid biopsy (circulating tumor DNA, ctDNA) from plasma is used to detect resistance mutations — particularly EGFR T790M and EGFR exon 20 C797S — that guide second-line therapy selection. Liquid biopsy adds a new specimen collection, processing, and result tracking workflow distinct from tissue biopsy coordination. VAs coordinate liquid biopsy specimen collection at progression, track result turnaround from Guardant Health, Foundation Medicine, or Tempus, and notify the thoracic oncologist when resistance mutation results are available for treatment planning.
Thoracic oncology programs building out this coordination infrastructure can explore specialized support at Stealth Agents.
Sources
- International Association for the Study of Lung Cancer. "IASLC Biomarker Testing Survey." 2023.
- National Comprehensive Cancer Network. "NCCN Guidelines: Non-Small Cell Lung Cancer." 2025.
- American Society of Clinical Oncology. "Targeted Therapy Prior Authorization Patterns." 2024.
- Foundation Medicine. "Liquid Biopsy Result Turnaround Data." foundationmedicine.com. 2024.